Phase II pilot study of FOLFOXIRI plus panitumumab in metastatic RAS wild-type left-sided colorectal cancer

Brief description of study

The purpose of this study is to evaluate the effectiveness (percent of patients with measurable response) of FOLFOXIRI and panitumumab for treatment of metastatic left sided, RAS wild-type colorectal cancer. The study will also evaluate the side effects of the combination of FOLFOXIRI and panitumumab, how well the combination of FOLFOXIRI and panitumumab works to treat this type of colorectal cancer and the length of time the treatment prevents the cancer from getting worse.


Clinical Study Identifier: s19-01307
ClinicalTrials.gov Identifier: NCT04169347
Principal Investigator: Paul E. Oberstein.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.